Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss pharmaceutical firm signed an exclusive agreement with Zealand Pharma to produce ...
Ozempic’s new frontier: The war on aging
Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.
The New Yorker2d
Who Gets to Determine Greenland’s Future?
Trump’s comments about purchasing the island sent shock waves through the Danish territory, and enlivened its independence ...
Researchers Find a Way To Trick the Body Into Changing How It Burns Fat
Scientists have identified the Plvap gene as a key regulator of metabolism during fasting. Disabling it in mice prevented the ...
US FDA to Hold off Action on Weight-Loss Drug Copies Pending Court Ruling
In its Monday update, the FDA clarified that state-licensed compounding pharmacies and outsourcing facilities — which make ...
The Pharma Letter2d
Russian generics producers start paying compensations to Novo Nordisk
Leading Russian drugmakers PSK Pharma and Promomed, which produce the analogues of Ozempic - a drug for the treatment of ...
Novo Nordisk shares fall on latest trial results for new obesity drug
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of ...
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Shocking stories of people who went blind after taking Ozempic and Mounjaro
Weight loss drugs like Ozempic, while transformative in combating obesity, have been linked to irreversible vision impairment ...
The rise of the Ozempic menu and how weight-loss drugs are changing dining out
With more diners skipping mains, drinking less and sharing starters because of weight-loss drugs, the traditional ...
Hims & Hers to Shut Down Dermatology Business Apostrophe
(Reuters) -Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the ...
Novo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher
The CEO of Novo Nordisk warned of the impact of tariffs on the pharmaceutical industry. Weight-loss drugs, including Ozempic ...